Tuberous Sclerosis Complex: Genetic counselling and perinatal follow-up.


Journal

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
ISSN: 1769-664X
Titre abrégé: Arch Pediatr
Pays: France
ID NLM: 9421356

Informations de publication

Date de publication:
Dec 2022
Historique:
entrez: 30 12 2022
pubmed: 31 12 2022
medline: 4 1 2023
Statut: ppublish

Résumé

Tuberous sclerosis is an autosomal dominant disorder almost fully penetrant with highly variable expression. Most cases are de novo and this diagnosis is sometimes considered during prenatal life in case of cardiac tumor, unique or multiple. The couple should be referred to a specialized tertiary prenatal care center for expertise and information. Fetal molecular testing of the two genes TSC1 and TSC2 is often informative. Prognosis determination for Tuberous Sclerosis remains a difficult task. Cardiac tumors can be sometimes worrying but only a minority will have a pejorative issue and most cases are asymptomatic without any therapeutic intervention needed. Only few cases need surgical or medical treatment. Patients with Tuberous Sclerosis can develop skin, eye, kidney or lung lesions later on, but they are either of limited consequence or treatable. The crux of the matter is the neurological involvement with frequent intellectual deficiency and epilepsy that can be drug-resistant. The absence of lesion on fetal brain MRI is not predictive of any prognosis and does not rule out Tuberous Sclerosis. De novo TSC2 mutation is a negative prognosis factor and conversely, an inherited TSC1 mutation is a more favorable one, but with a severe issue still possible. Facing this cautious prognosis, some couple may opt for termination of pregnancy while others decide to pursue it. It is then fundamental to set cardiac and neurological regular follow-up for these newborns. © 2022 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved.

Identifiants

pubmed: 36585068
pii: S0929-693X(22)00283-4
doi: 10.1016/S0929-693X(22)00283-4
pii:
doi:

Substances chimiques

Tumor Suppressor Proteins 0
Tuberous Sclerosis Complex 2 Protein 0
Tuberous Sclerosis Complex 1 Protein 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

5S3-5S7

Informations de copyright

Copyright © 2022 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

R Touraine (R)

Genetics Department, CHU-Hôpital Nord, F-42000 Saint Etienne, France. Electronic address: renaud.touraine@chu-st-etienne.fr.

Q Hauet (Q)

Nantes Université, CHU Nantes, Department of Pediatric Cardiology and Pediatric Cardiac Surgery, F-44000 Nantes, France; Nantes Université, CHU Nantes, INSERM, CIC FEA 1413, F-44000 Nantes, France.

I Harzallah (I)

Genetics Department, CHU-Hôpital Nord, F-42000 Saint Etienne, France.

A-E Baruteau (AE)

Nantes Université, CHU Nantes, Department of Pediatric Cardiology and Pediatric Cardiac Surgery, F-44000 Nantes, France; Nantes Université, CHU Nantes, INSERM, CIC FEA 1413, F-44000 Nantes, France; Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH